Depreotide

Summary

Depreotide is a technetium‑99m‑labeled synthetic analogue of somatostatin used as a radiopharmaceutical for single‑photon emission computed tomography (SPECT). It is employed primarily to image tumours that express somatostatin receptors, especially indeterminate pulmonary nodules and, in limited studies, bone metastases from breast cancer.

Mechanism of Action

Depreotide retains the cyclic peptide structure of somatostatin and binds with high affinity to somatostatin receptor subtypes 2, 3 and 5 on the surface of certain tumour cells. After intravenous injection, the 99mTc label emits gamma photons that can be detected by SPECT. Receptor‑mediated uptake concentrates the tracer in receptor‑positive lesions, allowing visualisation of malignant tissue while background activity remains low.

What the Research Shows

Diagnostic studies have explored 99mTc‑depreotide SPECT in several settings. In a small breast‑cancer cohort (n=12), depreotide showed 62.5% sensitivity but 100% specificity for bone metastases, compared with bone scintigraphy’s higher sensitivity but lower specificity. A meta‑analysis of solitary pulmonary nodule (SPN) investigations (seven depreotide studies) reported pooled sensitivity of 0.95 and specificity of 0.82, comparable to FDG‑PET and dynamic CT/MR. A direct head‑to‑head trial of 28 SPN patients found depreotide SPECT sensitivity of 88.9% versus 94.4% for FDG‑PET, with similar specificity; the authors suggested combined use might improve accuracy. Reviews note depreotide’s high affinity for SSTR2/3/5 and its regulatory approval in Europe (and historically in the US) for lung tumour imaging, but the compound has since been withdrawn from the market.

Reported Benefits

Evidence indicates that depreotide SPECT provides high specificity for receptor‑positive lesions, helping to differentiate malignant from benign pulmonary nodules and to characterise tumour biology. Its ability to visualise somatostatin‑receptor expression may inform prognosis and guide hormonal therapy decisions, as suggested in the breast‑cancer bone‑metastasis study. The radiopharmaceutical is relatively inexpensive to produce compared with other labelled peptides, and its gamma emission is compatible with widely available SPECT cameras.

Limitations of the Evidence

Most clinical data derive from small, single‑centre studies; large‑scale prospective trials are lacking. Sensitivity for detecting malignancy can be lower than that of FDG‑PET, and comparative performance varies across tumour types. The compound’s withdrawn status limits current availability, and regulatory approvals differ by region. Consequently, definitive conclusions about its superiority or equivalence to other imaging modalities remain uncertain.

Safety Considerations

Depreotide is administered as a radiopharmaceutical; reported adverse events are rare and generally limited to mild injection‑site reactions. The primary safety consideration is radiation exposure, which is comparable to other 99mTc‑based scans. No systemic toxicities related to somatostatin‑receptor activation have been described in the cited literature. Standard radiation‑protection guidelines apply, particularly in pregnant or lactating patients.

How It Is Administered

Depreotide is supplied as a kit for radiolabelling with technetium‑99m and is injected intravenously. After administration, imaging is performed with SPECT, often combined with CT for anatomical correlation. The procedure follows routine nuclear‑medicine protocols for radiotracer dosing and image acquisition.

Routes of Administration

Goals & Uses

• Carcinoid tumor stagingDiagnostic ImagingModerate
• Staging of lung cancerOncology ImagingModerate
• Detection of somatostatin receptor-positive tumorsOncology ImagingModerate
• Characterization of solitary pulmonary nodulesDiagnostic ImagingHigh
• Neuroendocrine tumor localizationDiagnostic ImagingHigh

Contraindications

• Hypersensitivity to depreotide or somatostatin analoguesAllergyHigh
• Known hypersensitivity to octreotide or indium‑111AllergyHigh
• PregnancyPopulationHighPotential fetal risk or insufficient safety data
• LactationReproductiveModerate
• BreastfeedingPopulationHighPotential transfer into breast milk or insufficient safety data

Adverse Effects

• Transient abdominal painGastrointestinalUncommon
• Radiation exposureRadiologicalCommon
• Injection site reactionsLocalCommon
• HeadacheNeurologicUncommonPain in the head or upper neck
• Hypersensitivity/allergic reactionImmunologicalRare
• FlushingVascularCommonWarmth and redness of the skin
• NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
• Radiation‑induced leukopeniaHematologicRare

Drug Interactions

• Octreotide / somatostatin analoguesModerate
• Somatostatin analog therapy (e.g., octreotide LAR)Low
• Other radiopharmaceuticalsModerate

Population Constraints

• Renal impairmentOrgan ImpairmentRelative
• Pediatric patientsAgeRelative
• Elderly patientsAgeRelative

Regulatory Status

• European UnionApprovedApproved: Diagnostic imaging of neuroendocrine tumorsDepreotide authorized in several EU member states
• United StatesApprovedApproved: Localization of somatostatin receptor positive tumorsmarketed as Octreoscan; Depreotide brand not used in US
• United KingdomWithdrawnwithdrawn from market in 2022

Approved by the FDA in 1999 for imaging of solitary pulmonary nodules. Also approved in Europe (NeoSPECT). Withdrawn from the US and EU markets around 2004–2005 for commercial/business reasons, not for safety concerns.

Evidence & Sources

• 99mTc depreotide scan compared with 99mTc-MDP bone scintigraphy for the detection of bone metastases and prediction of response to hormonal treatment in patients with breast cancer
  Journal ArticleModerateVan Den Bossche B, et al.2004-01-01T00:00:00.000000Z
• Solitary pulmonary nodules: meta-analytic comparison of cross-sectional imaging modalities for diagnosis of malignancy
  Journal ArticleHighCronin P, et al.2008-01-01T00:00:00.000000Z
• [(99m)Tc]Cyclo(L-homocysteinyl-N-methyl-L-phenylalanyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl), (1‡1´)-sulfide with 3-[(mercaptoacetyl)amino]-L-alanyl-L-lysyl-L-cysteinyl-L-lysinamide
  Journal ArticleModerateChopra A2004-01-01T00:00:00.000000Z
• Efficiency of 18F-FDG and 99mTc-depreotide SPECT in the diagnosis of malignancy of solitary pulmonary nodules
  Journal ArticleModerateHalley A, et al.2005-01-01T00:00:00.000000Z
• New trends in peptide receptor radioligands
  Journal ArticleModerateVirgolini I, et al.2001-01-01T00:00:00.000000Z
• Nuclear medicine imaging of lung cancer
  Journal ArticleModerateGoldsmith SJ, Kostakoglu L2000-01-01T00:00:00.000000Z

Frequently Asked Questions